FDA Approves Mirdametinib for Neurofibromatosis Type 1

The kinase inhibitor is now approved for adults and children aged ≥ 2 years with neurofibromatosis type 1 who have unresectable symptomatic plexiform neurofibromas.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-approves-mirdametinib-neurofibromatosis-type-1-2025a10003l8?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?